These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36919343)

  • 21. Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma.
    Fan HC; Chen CM; Chi CS; Tsai JD; Chiang KL; Chang YK; Lin SZ; Harn HJ
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30625996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma.
    Ahmad F; Dixit D; Sharma V; Kumar A; Joshi SD; Sarkar C; Sen E
    Cell Death Dis; 2016 May; 7(5):e2213. PubMed ID: 27148686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas.
    Tchirkov A; Rolhion C; Kémény JL; Irthum B; Puget S; Khalil T; Chinot O; Kwiatkowski F; Périssel B; Vago P; Verrelle P
    Br J Cancer; 2003 Feb; 88(4):516-20. PubMed ID: 12592364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma.
    Patel R; Shervington L; Lea R; Shervington A
    Brain Res; 2008 Jan; 1188():173-81. PubMed ID: 18021753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Directions in the Treatment of Glioblastoma.
    Reitman ZJ; Winkler F; Elia AEH
    Semin Neurol; 2018 Feb; 38(1):50-61. PubMed ID: 29548052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
    Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
    Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
    Weller M; Reifenberger G
    Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
    Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
    Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lentiviral vector mediated siRNA knock-down of hTERT results in diminished capacity in invasiveness and in vivo growth of human glioma cells in a telomere length-independent manner.
    Zhao P; Wang C; Fu Z; You Y; Cheng Y; Lu X; Lu A; Liu N; Pu P; Kang C; Salford LG; Fan X
    Int J Oncol; 2007 Aug; 31(2):361-8. PubMed ID: 17611693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target?
    Di Nunno V; Aprile M; Bartolini S; Gatto L; Tosoni A; Ranieri L; De Biase D; Asioli S; Franceschi E
    Cells; 2023 Dec; 13(1):. PubMed ID: 38201248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential hTERT mRNA processing between young and older glioma patients.
    Shervington A; Patel R
    FEBS Lett; 2008 May; 582(12):1707-10. PubMed ID: 18435920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme.
    Falchetti ML; Pallini R; D'Ambrosio E; Pierconti F; Martini M; Cimino-Reale G; Verna R; Maira G; Larocca LM
    Int J Cancer; 2000 Dec; 88(6):895-901. PubMed ID: 11093811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid progression of an IDH-wild type histological low-grade glioma harbouring TERT promoter mutation and diffuse CD34 expression: a case report.
    Wang H; Tan C; Xu T; Li W
    Folia Neuropathol; 2021; 59(1):104-111. PubMed ID: 33969682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis.
    Fogli A; Demattei MV; Corset L; Vaurs-Barrière C; Chautard E; Biau J; Kémény JL; Godfraind C; Pereira B; Khalil T; Grandin N; Arnaud P; Charbonneau M; Verrelle P
    J Neurooncol; 2017 Nov; 135(2):381-390. PubMed ID: 28755323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status.
    Ito H; Kanzawa T; Miyoshi T; Hirohata S; Kyo S; Iwamaru A; Aoki H; Kondo Y; Kondo S
    Hum Gene Ther; 2005 Jun; 16(6):685-98. PubMed ID: 15960600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study on combined gene therapy for malignant gliomas transfected with antisense hTERT/PTEN in vitro and in vivo].
    You YP; Fu Z; Zhao P; Wang CZ; Liu N; Lu AL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):605-9. PubMed ID: 17160935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
    Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells.
    Takeuchi H; Kanzawa T; Kondo Y; Komata T; Hirohata S; Kyo S; Kondo S
    Int J Oncol; 2004 Jul; 25(1):57-63. PubMed ID: 15201989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
    Hewer E; Phour J; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):430-436. PubMed ID: 32068851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.